Background. Pneumococcal conjugate vaccines are important for the prevention of serious illness and death among infants. Factors associated with pneumococcal conjugate vaccine immunogenicity have not been explored.
at various ages in the same population [8] [9] [10] . Most immunogenicity studies have evaluated the response to some of the doses [1] [2] [3] [4] [5] [6] [7] . No studies have evaluated predictors of the immune response to PCV. Given that PCVs are now being seriously considered for global introduction, it is critical to understand the determinants of immunogenicity.
Some Native American populations-notably Alaska Natives, Navajo, and White Mountain Apaches-have higher rates of pneumococcal nasopharyngeal colonization and invasive pneumococcal disease than the general US population [11] [12] [13] , epidemiologic characteristics similar to those found in many developing countries. The basis for this increased risk is unknown; hypotheses include household crowding, indoor air pollution, infection pressure from viral respiratory illnesses, and host factors (i.e., reduced immune response to polysaccharide antigens). We conducted an efficacy trial of PnCRM7 among Navajo and White Mountain Apache Indians [14] and demonstrated efficacy against vaccine-serotype invasive pneumococcal disease of 76.8% (95% confidence interval [CI] , Ϫ9.4 to 95.1), similar to that found among children in The Gambia (77% [95% CI, 51 to 90]) and among HIV-negative children in South Africa (83% [95% CI, 39 to 97]). We report here the immunogenicity results of the American Indian PnCRM7 trial.
METHODS

Study description.
This was a group-randomized efficacy trial conducted between April 1997 and May 2000 on the Navajo and White Mountain Apache reservations in the southwestern United States. All children in a defined community who were 6 weeks to 23 months of age and whose parents or guardians provided consent for participation were assigned to receive the same vaccine [15] . The intervention vaccine was PnCRM7, and the control vaccine was Neisseria meningitidis group C protein conjugate vaccine (MnCC; Wyeth Vaccines) [14] .
Subjects enrolled between 6 weeks and 6 months of age (primary efficacy [PE] group) received 3 doses of vaccine 2 months apart (4 weeks minimum) and a booster dose at 12-15 months of age (at least 2 months after dose 3). Subjects enrolled between 7 and 11 months of age (infant catch-up [ICU] group) received 2 doses of vaccine 2 months apart (4 weeks minimum) and a booster dose at 12-15 months of age (at least 2 months after dose 2). Subjects enrolled between 12 and 23 months of age (toddler catch-up [TCU] group) received 2 doses of vaccine at least 2 months apart. Children enrolled in the study also received routine childhood vaccines (table 1) .
A subset of the efficacy trial participants were enrolled in a nested immunogenicity evaluation. Their blood was drawn at predetermined times according to their vaccine schedule (table 1) .
Antibody determination by ELISA. All serum samples were tested at Wyeth Vaccines in a blinded fashion for serotypespecific anti-pneumococcal IgG antibodies by a standard ELISA without 22F absorption [16] and for Haemophilus influenzae type b (Hib) polyribosylribitolphosphate polysaccharide (PRP) IgG [17] . The pneumococcal antibody concentration limit of quantitation was 0.01 mg/mL; samples with a value below this were assigned a value of 0.005 mg/mL. Statistical analysis. Only participants' observations meeting per-protocol definitions (available from authors) were included in the analyses, up to the point of the first protocol violation. For any particular sampling time, all eligible observations were included.
At each sampling time and for each vaccine serotype, the geometric mean concentration (GMC) of antibodies (with a standard 95% confidence interval [CI] ) and reverse cumulative distribution curves were calculated. Comparisons of responses over time and across serotypes were made using the Spearman rank correlation coefficients for the logarithms of antibody concentrations. Proportions of children achieving various antibody concentrations are reported with 95% CIs. We used 0.35 mg/ mL (the proposed correlate of protection against invasive disease derived by combining results of the American Indian, northern California, and South African PCV efficacy trials [18, 19] ), 1.0 mg/mL (the correlate against invasive disease efficacy in the American Indian PnCRM7 efficacy trial [20] ), and 5.0 mg/mL (the proposed correlate of protection against nasopharyngeal colonization [21] ) as antibody concentrations of interest in our analysis of response to PnCRM7.
Among subjects in the PE group, we explored the effects of maternally derived antibody, age at dose 1, sex, dosing interval, and breast-feeding status on the antibody response to dose 1, 3, and 4. We fitted multiple linear regression (MLR) models using log-transformed antibody concentrations. For the dose 1 analysis, we also adjusted for the expected deterioration in maternally derived antibody, to separate out the parameter of interest, infant response to vaccine, from the remaining maternal antibody. We used MLR to model the reduction in maternally derived pneumococcal antibody from before to after dose 1 among the children receiving MnCC. Using this model, we predicted the post-dose 1 serotype-specific pneumococcal antibody concentration for each PnCRM7-vaccinated subject on the basis of their pre-dose 1 antibody concentration and other covariates. Using the logarithmic values, the predicted post-dose 1 value was subtracted from the observed post-dose 1 value to obtain the infant response to vaccine. Test results were considered to be statistically significant if the 2-tailed P value was !.05.
Ethics and consent. The study was approved by the institutional review boards of the Johns Hopkins School of Medicine, the Navajo Nation, the Phoenix Area Indian Health Service, and the US Indian Health Service. Tribal approval was given by the Navajo Nation and the White Mountain Apache figure  1 ). The proportion of PnCRM7-vaccinated subjects achieving an antibody concentration у0.35 mg/mL after dose 1 ranged by serotype from 20.4% to 78.7% (figure 1). The proportion of subjects achieving an antibody concentration у0.35 mg/mL after dose 3 was greater than that after dose 2 only for serotypes 6B ( ) and 23F ( ). The proportion of subjects P p .01 P ! .001 achieving an antibody concentration у1.0 mg/mL after dose 3 was greater than that after dose 2 for all serotypes except type 4 (for serotype 14, ; for all others, ). The pro-P p .02 P ! .001 portion of subjects who achieved a serotype-specific antibody concentration у5.0 mg/mL increased from after dose 2 to after dose 3 for all serotypes (for 4, ; for all others, P p .009 P ! ) and from after dose 3 to after dose 4 for all serotypes .001 except type 14 ( , for all). Dose 3 stimulated a large P ! .001 antibody response, suggestive of a booster or memory response, for serotype 6B only ( figure 2 ). An antibody response to a fourth dose of PnCRM7 large enough to suggest a memory response was seen for all serotypes (table 2) .
Although the proportion of subjects in the PE group achieving an antibody concentration у0.35 mg/mL did not increase after dose 3 compared with that after dose 2 for most serotypes, the antibody GMCs achieved after dose 3 were significantly higher than those achieved after dose 2 for all serotypes except type 4 (figure 2). By 9-12 months after dose 4, there was up to a 10-fold reduction in serotype-specific antibody concentrations, compared with those achieved immediately after dose 4, for all serotypes except type 19F; the antibody concentrations were higher for all serotypes among those who received PnCRM7 than among those who received MnCC.
Pneumococcal immunogenicity among subjects immunized between 7 and 23 months of age. Significant antibody responses were achieved for all serotypes after 2 doses of PnCRM7 among subjects initiating vaccination between 7 and 11 months (the ICU group) and after 1 dose for subjects initiating between 12 and 23 months (the TCU group), compared with the responses in subjects receiving MnCC (table 3) . The proportion of subjects achieving an antibody concentration у0.35 mg/mL ranged by serotype from 82% to 94% after dose 2 in the ICU group and from 64% to 95% after dose 1 in the TCU group (figure 3). The last dose administered in each vaccine series elicited an increase in the antibody GMC of sufficient magnitude to suggest a booster response for serotypes 6B, 14, and 23F in the ICU group and for serotypes 6B, 14, 19F, and 23F in the TCU group. For the remaining serotypes, the magnitude of the increase in antibody concentration relative to that from the preceding dose was not substantial enough to unequivocally indicate a booster response.
Effects of maternally derived antibody, breast-feeding, age at first dose, sex, and dosing interval on the response to PnCRM7 in the first year of life. We evaluated the effects of maternally derived antibody, breast-feeding, age at first dose, sex, and dosing interval on the pneumococcal antibody response after dose 1, 3, and 4. In a univariate analysis, each variable was associated with the vaccine response for at least 1 serotype and dose (data not shown). We retained all variables in MLR models created for each serotype and each dose.
Increasing maternal pneumococcal antibody concentrations were associated with a lower response to dose 1 . There was no association between high maternal antibody .05 concentrations and the response to dose 4 for any serotype. For some combinations of serotype and dose, there were associations between other variables in the model and the response to vaccine, but these were not consistently observed (data not shown).
The proportion of subjects who achieved an antibody concentration у0.35 mg/mL after dose 1 varied by maternal antibody tertile; the middle tertile had the lowest proportion for serotypes 9V, 14, 18C, 19F, and 23F, whereas the highest tertile had the lowest proportion for serotype 4 and the highest proportion for serotypes 6B, 14, 19F, and 23F. Among those subjects with intermediate pre-dose 1 antibody concentrations, maternal antibody both interfered with response to vaccine and was insufficiently high to sustain levels у0.35 mg/mL through the first several months of life. The proportion of subjects achieving an antibody concentration у0.35 mg/mL after dose 3 did not vary by maternal antibody tertile except for serotype 4; those children with intermediate maternal antibody concentrations had the lowest proportion achieving the threshold.
Correlation between responses to PnCRM7 serotypes. The antibody response of a child to a given serotype correlated with Relationship between individual responses to various PnCRM7 doses. We evaluated the response of a given child to various doses of vaccine. For all serotypes, there was a significant positive correlation between the serotype-specific antibody response of PE subjects to 1 dose of PnCRM7 and their response to the subsequent dose (Spearman correlation coefficients, 0.24-0.58;
). P ! .05 Effect of age on the immunogenicity of PnCRM7. Because children could enroll between 2 and 23 months of age, we assessed the effect of age on the immunogenicity of PnCRM7, controlling for the number of preceding doses. With age as a categorical variable, we compared the immunogenicity of PnCRM7 among children in various age strata (table 4). Dose 1 immunogenicity was significantly greater for all serotypes except type 14 when administered at у12 months of age than when administered at 2-4 months of age. There was no enhanced immunogenicity by delaying the initiation of dose 1 to 4 months of age.
The immunogenicity of dose 2 did not vary by age when administered at any time between 4 and 13 months. Dose 2 immunogenicity was, however, significantly greater when dose 1 was given at 12-23 months than at 2-4 months of age. There were no differences in the immunogenicity of dose 3 administered to infants who initiated their series at any time between 2 and 11 months of age. Delaying the initiation of the vaccine series until the second year of life resulted in enhanced immunogenicity for doses 1 and 2 at the expense of administering vaccine during the first year of life.
Comparisons of the GMCs of antibodies after the priming series show that a 3-dose priming series is significantly more immunogenic than a 2-or 1-dose priming series, even when those series are administered later during infancy or during the second year of life (tables 2-4). Similarly, the final dose in each series resulted in higher GMCs when administered after a 3-dose priming series than after a 2-or 1-dose priming series, even when the latter were administered at ages older than those for the 3-dose priming series. The final dose in each series resulted in an equivalent proportion of subjects achieving an antibody concentration у0.35 mg/mL for all serotypes (data not shown).
Hib-meningococcal outer membrane protein complex (OMP) immunogenicity. After dose 1, the proportion of subjects with PRP antibody concentrations у1.0 mg/mL did not differ by concomitant administration of PnCRM7, MnCC, or neither, as measured in historical control subjects (52%, 59%, and 51%, respectively) [22] . 
DISCUSSION
This is 1 of only 2 reports evaluating the immunogenicity of PnCRM7 after each of the 4 doses used in the US infant immunization schedule [10] and exploring the comparative immunogenicity of various infant and toddler vaccine schedules in a single population [9] . The GMCs of antibodies after PnCRM7 vaccination in the present American Indian children are equivalent to or greater than those observed in children in the general populations of the United States [1, 2] , the United Kingdom [9] , Finland [10] , The Gambia [6] , or South Africa [8] . Thus, there is no evidence that high rates of invasive pneumococcal disease among American Indian populations are attributable to an impaired immune response to pneumococcal polysaccharide antigens, at least as they are presented in the form of PCVs.
Maternal antibody interference with the immune response to viral vaccines, such as measles, and bacterial polysaccharide vaccines, such as Hib, is well recognized [23, 24] . We have shown that increasing maternal pneumococcal antibody concentration is associated with a reduced response to PCV when administered during the first 6 months of life. Maternal antibodies to the carrier protein (i.e., diphtheria), which could be associated with the response to PnCRM7 in infants, were not assessed [25, 26] . There was no evidence of maternal pneumococcal antibody interference of the memory response as assessed by the post-dose 4 antibody response. The distribution of maternal pneumococcal antibody concentrations in this population may differ from that of other populations in which early PCV administration is considered (table 2). The proportions of subjects with antibody concentrations у0.35 mg/mL before dose 1 among PnCRM7-vaccinated children were 20%, 54%, 44%, 51%, 34%, 59%, and 39% for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, respectively.
Other variables explored, such as sex, breast-feeding, age at dose 1 (between 2-6 months), and dosing interval, did not predict a response to PCV over the range that they were observed. For any dose of PnCRM7, a subject's response to 1 serotype correlated positively with his or her response to other serotypes in the vaccine. Also, a subject's response to a given dose of vaccine correlated positively with his or her response to a subsequent dose of vaccine.
The catch-up immunization schedules for children initiating vaccine at 7-23 months of age were highly immunogenic; both a single dose and a second dose administered during the second year of life were significantly more immunogenic than those doses administered early during infancy. However, there was no enhanced immunogenicity by delaying the immunization schedule within the first year of life. Higher antibody GMCs were achieved when the final dose was administered after a 3-dose primary series than after a 2-or 1-dose primary series, even though the latter were administered at older ages. The proportion of subjects who achieved an antibody concentration у0.35 mg/mL after the final dose in the series did not differ according to the series administered, but the series did affect the proportion achieving an antibody concentration у5.0 mg/mL.
Compared with the GMC after dose 2 of PnCRM7 during infancy, dose 3 resulted in a significantly greater GMC for all serotypes except type 4. The impact of dose 3 observed here was similar to that seen in infants in the general US population, in which only serotypes 4 and 19F remained unchanged [1] . By contrast, there were no significant GMC increases for any serotype among infants in the United Kingdom who received a 2-dose versus a 3-dose priming series [9] . In that study, the 3-dose priming series was given at 2, 3, and 4 months of age; the shorter interval between doses, compared with that given in the United States (i.e., 2, 4, and 6 months of age), may reduce the immune response and explain why no differences in the 2-dose and 3-dose priming series GMCs were observed. This hypothesis is supported by the observation that the postdose 3 GMCs in American Indian children were greater than those in the UK infants for all serotypes except types 14 and 19F, whereas there were almost no differences in the post-dose 2 GMCs between the 2 populations. Other factors, such as population variability or natural exposure to pneumococcal antigens through nasopharyngeal carriage, may also contribute to observed differences in immunogenicity; controversy exists about the impact of differences in ELISAs (i.e., absorption with 22F) [20, 27] .
Although the GMCs were greater after dose 3 than after dose 2 for most serotypes, the proportion of subjects who achieved an antibody concentration у0.35 mg/mL increased for types 6B and 23F only, which is consistent with findings from several other studies [1, 28, 29] . There was a significant increase in the proportion of infants achieving an antibody concentration у5.0 mg/mL-a proposed threshold for protection against nasopharyngeal colonization [21] -for all but 1 serotype. Thus, the need for a third priming dose is not entirely clear. Significant efficacy against invasive disease has been documented in postlicensure US studies for 2-dose priming schedules, although there appears to be added efficacy conferred by a third priming dose [30, 31] . Our immunogenicity data suggest that the third dose in infancy may play a significant role in the indirect effects of vaccine by increasing the proportion of subjects with antibody concentrations required for protection against nasopharyngeal colonization. The relative longevity of the immune response after a 2-dose or 3-dose priming schedule is not known. As exposure and natural boosting to vaccine-serotype strains is reduced in the community through PCV use, the longevity of the primary immune response may become very important. The impact of various reduced-dose schedules in infancy on direct effects, carriage, and indirect effects should be evaluated further.
The present study also assessed the pneumococcal antibody concentrations beyond the immediate post-dose 4 period. The GMCs and the proportion of subjects with concentrations у5.0 or у0.35 mg/mL fell significantly for most vaccine serotypes during the 12 months after the administration of the fourth dose, similar to observations in Finnish infants [10] . Despite the decline in antibody concentrations, the proportion with concentrations у0.35 mg/mL remained significantly higher in PnCRM7-vaccinated than in MnCC-vaccinated subjects. The proportion of PnCRM7-vaccinated subjects with an antibody concentration у5.0 mg/mL was !10% for most serotypes at 12 months after dose 4. If passive transudation of serum anticapsular antibody is the primary means of protection against vaccine-serotype nasopharyngeal acquisition, it is not clear how the reduction in vaccine-serotype nasopharyngeal colonization is maintained over the long term. A clearer understanding of the local and systemic immune mechanisms of nasopharyngeal protection are needed to fully interpret and predict the impact of pneumococcal vaccine in communities.
We observed no interference of PnCRM7 with the Hib-OMP vaccine antibody response. This is critical for epidemiologic settings in which invasive Hib disease occurs very early during life, necessitating a conjugate Hib vaccine that is highly immunogenic after dose 1. The present study is the only one to have evaluated concomitant Hib-OMP and PCV administration.
The limitations of this study include the lack of racial diversity among the children studied and the limited sample size of the older age cohorts, compared with that of the younger cohorts. In conclusion, the present study has demonstrated the relative merits of various PCV schedules through the first 2 years of life. It has also shown that high maternal antibody concentrations are correlated with a reduced immune response to PCV during infancy but do not interfere with the induction of the immune memory response to PnCRM7. As we learn more about the correlates of protection against nasopharyngeal acquisition and the long-term community effect of the vaccine, our understanding of immunogenicity by dose and age will be critical for optimizing vaccine schedules and vaccine impact.
